OBJECTIVE To compare the efficacy and safety of a synthesized candidate adamgammadex
with the only marketed selective relaxant binding agent sugammadex. METHODS Forty …

Background: Rapid reversal of neuromuscular block after surgery and anesthesia is often
necessary. Here, we reported the primary efficacy and safety data from a phase IIa study on …

The rapid reversal of deep neuromuscular blockade (NMB) is important but remains
challenging. This study aimed to evaluate the efficacy and safety of adamgammadex versus …

This current phase II clinical trial was to compare the effect and safety of adamgammadex, a
new cyclodextrin-based selective relaxant binding agent, with sugammadex to reverse …

Neuromuscular blockers (NMBs) selectively block neuromuscular transmission at the N2-
nicotinic receptor on motor neurons to paralyze skeletal muscles, and are mainly used to …

Aims The aim of this study was to investigate the effectiveness, safety and pharmacokinetics
of adamgammadex in surgical patients. Methods Forty‐eight patients aged 18–64 years old …

Background Preliminary clinical trials of adamgammadex, a new cyclodextrin-based
selective reversal agent, have demonstrated its efficacy in reversing neuromuscular block by …

Abstract Background and Objective: Sugammadex facilitates rapid reversal of rocuronium-
and vecuronium-induced neuromuscular blockade. This study aimed to evaluate the safety …

Sugammadex (Bridion®) is a modified γ-cyclodextrin that reverses the effect of the steroidal
nondepolarizing neuromuscular blocking agents rocuronium and vecuronium. Intravenous …

Background Sugammadex (Org 25969) forms a complex with steroidal neuromuscular
blocking agents, thereby reversing neuromuscular block. This study investigated the dose …